|0.1355||-0.0005||-0.37%||Vol 2.97M||1Y Perf -92.41%|
|Dec 2nd, 2022 16:00 DELAYED|
|- -||0.00 -0.22%|
|Target Price||6.50||Analyst Rating||Hold 3.00|
|Potential %||4.70K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||★★★★+ 59.64|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Price Range Ratio 52W %||2.89||Earnings Rating||Buy|
|Market Cap||28.03M||Earnings Date||10th Nov 2022|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.07|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||4.57M|
|Avg. Monthly Volume||3.10M|
|Avg. Quarterly Volume||5.73M|
VistaGen Therapeutics Inc. (NASDAQ: VTGN) stock closed at 0.1355 per share at the end of the most recent trading day (a -0.37% change compared to the prior day closing price) with a volume of 2.97M shares and market capitalization of 28.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. VistaGen Therapeutics Inc. CEO is Shawn K. Singh.
The one-year performance of VistaGen Therapeutics Inc. stock is -92.41%, while year-to-date (YTD) performance is -93.05%. VTGN stock has a five-year performance of -83.27%. Its 52-week range is between 0.0768 and 2.11, which gives VTGN stock a 52-week price range ratio of 2.89%
VistaGen Therapeutics Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.86, a price-to-sale (PS) ratio of -136.52, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -91.63%, a ROC of -110.25% and a ROE of -117.34%. The company’s profit margin is -%, its EBITDA margin is 34 330.70%, and its revenue ttm is $-185 600.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from VistaGen Therapeutics Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.07 for the next earnings report. VistaGen Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for VistaGen Therapeutics Inc. is Hold (3), with a target price of $6.5, which is +4 697.05% compared to the current price. The earnings rating for VistaGen Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
VistaGen Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
VistaGen Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.43, ATR14 : 0.02, CCI20 : -10.07, Chaikin Money Flow : -0.08, MACD : 0.00, Money Flow Index : 57.83, ROC : -14.83, RSI : 46.94, STOCH (14,3) : 32.22, STOCH RSI : 0.86, UO : 37.68, Williams %R : -67.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of VistaGen Therapeutics Inc. in the last 12-months were: Jerrold D. Dotson (Option Excercise at a value of $18 750), Jerry B. Gin (Buy at a value of $17 870), Reid G. Adler (Buy at a value of $50 910), Shawn K. Singh (Buy at a value of $103 200), Shawn K. Singh (Option Excercise at a value of $100 000)
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.